Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;24(8):441-452.
doi: 10.1038/gt.2017.41. Epub 2017 May 15.

Engineering liposomal nanoparticles for targeted gene therapy

Affiliations
Review

Engineering liposomal nanoparticles for targeted gene therapy

C Zylberberg et al. Gene Ther. 2017 Aug.

Abstract

Recent mechanistic studies have attempted to deepen our understanding of the process by which liposome-mediated delivery of genetic material occurs. Understanding the interactions between lipid nanoparticles and cells is still largely elusive. Liposome-mediated delivery of genetic material faces systemic obstacles alongside entry into the cell, endosomal escape, lysosomal degradation and nuclear uptake. Rational design approaches for targeted delivery have been developed to reduce off-target effects and enhance transfection. These strategies, which have included the modification of lipid nanoparticles with target-specific ligands to enhance intracellular uptake, have shown significant promise at the proof-of-concept stage. Control of physical and chemical specifications of liposome composition, which includes lipid-to-DNA charge, size, presence of ester bonds, chain length and nature of ligand complexation, is integral to the performance of targeted liposomes as genetic delivery agents. Clinical advances are expected to rely on such systems in the therapeutic application of liposome nanoparticle-based gene therapy. Here, we discuss the latest breakthroughs in the development of targeted liposome-based agents for the delivery of genetic material, paying particular attention to new ligand and cationic lipid design as well as recent in vivo advances.

PubMed Disclaimer

References

    1. J Control Release. 2010 Apr 19;143(2):233-42 - PubMed
    1. Top Curr Chem. 2010;296:191-226 - PubMed
    1. J Pept Sci. 2008 Apr;14(4):469-76 - PubMed
    1. Int J Mol Med. 2007 Oct;20(4):429-37 - PubMed
    1. Gene Ther. 2009 Jan;16(1):52-9 - PubMed